journal article·2018-10-31Open access

Effects of N-terminal and C-terminal modification on cytotoxicity and cellular uptake of amphiphilic cell penetrating peptides

Mehdi Soleymani-Goloujeh, Ali Nokhodchi, Mehri Niazi, Saeedeh Najafi-Hajivar, Javid Shahbazi-Mojarrad, Nosratollah Zarghami, Parvin Zakeri-Milani, Ali Mohammadi, Mohammad Karimi, Hadi Valizadeh

Abstract

PURPOSE: To assess the effect of "N-Acetylation and C-Amidation" on the cellular uptake, cytotoxicity and performance of amphiphilic cell penetrating peptides (CPP) loaded with methotrexate (MTX). METHODS: Several CPPs were synthesized by solid phase peptide synthesis method. Some of these sequences were modified with pyroglutamic acid at N-terminus and benzylamine or memantine at C-terminus. The resultant nanomaterials were prepared due to the physical linkage between CPPs and MTX. The internalization and cytotoxicity of both CPP-MTX bioconjugates and unmodified CPPs against MCF-7 human breast adenocarcinoma cells was evaluated. RESULTS: N-l and C-terminal modification did not alter the toxicity of CPPs. Physical linkage of CPPs with MTX resulted in a lower drug loading efficiency in comparison with chemically conjugated CPP-MTX bio-conjugates. Both nano-complexes increase the toxic effect of MTX on MCF-7 cells. Furthermore, N- and C-terminal modification may cause a tangible reduction in cellular uptake of CPPs. CONCLUSION: In conclusion, it was shown that cytotoxicity of modified peptides which were physically linked with MTX, considerably higher than both physically loaded unmodified peptides and chemically conjugated peptides with MTX. Also, cell internalization was reduced after peptide end-protection. These findings confirmed the effectiveness of N- and C-terminal modifications on cell viability and CPPs internalization.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Supramolecular Self-Assembly in Materials · Polydiacetylene-based materials and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences

Department of Stem Cells and Developmental Biology at Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR

Pharmaceutics Research Laboratory, School of Life Sciences, University of Sussex

Student Research Committee, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences

Biotechnology Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences

Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences

Liver and Gastrointestinal Diseases Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences

Immunology Research Center, Tabriz University of Medical Sciences

Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences

Funding

Drug Applied Research Center · Tabriz University of Medical Sciences

References (40)

Show source-provided references
1. 10.1208/s12248-008-9029-410.1208/s12248-008-9029-4 ↗
2. 10.1016/j.bbamem.2005.10.00610.1016/j.bbamem.2005.10.006 ↗
3. 10.1016/j.biopha.2016.08.06010.1016/j.biopha.2016.08.060 ↗
4. 10.1080/17425255.2016.119618610.1080/17425255.2016.1196186 ↗
5. 10.1080/21691401.2017.136032510.1080/21691401.2017.1360325 ↗
6. 10.1016/j.febslet.2013.04.03110.1016/j.febslet.2013.04.031 ↗
7. 10.1002/jps.2012510.1002/jps.20125 ↗
8. 10.1515/BC.2003.04410.1515/BC.2003.044 ↗
9. 10.1016/j.copbio.2006.10.00210.1016/j.copbio.2006.10.002 ↗
10. 10.1021/bi300454k10.1021/bi300454k ↗
11. 10.1074/jbc.M00754020010.1074/jbc.M007540200 ↗
12. 10.1016/j.ejpb.2003.09.00610.1016/j.ejpb.2003.09.006 ↗
13. 10.3109/21691401.2015.103190610.3109/21691401.2015.1031906 ↗
14. 10.1080/21691401.2016.120005910.1080/21691401.2016.1200059 ↗
15. Zakeri-Milani P, Mussa Farkhani S, Shirani A, et al. Cellular uptake and anti-tumor activity of gemcitabine conjugated with new amphiphilic cell penetrating peptides. EXCLI Journal. 2017;16:650–662.
16. 10.1080/21691401.2017.137901610.1080/21691401.2017.1379016 ↗
17. 10.1039/C5CC00501A10.1039/C5CC00501A ↗
18. 10.1080/21691401.2017.130721410.1080/21691401.2017.1307214 ↗
19. 10.1039/c2sm25713k10.1039/c2sm25713k ↗
20. 10.1021/nn203343z10.1021/nn203343z ↗
21. 10.1016/j.biomaterials.2014.02.03110.1016/j.biomaterials.2014.02.031 ↗
22. 10.1039/C2SM06923G10.1039/C2SM06923G ↗
23. 10.1039/c3cc41896k10.1039/c3cc41896k ↗
24. 10.1021/ja904411z10.1021/ja904411z ↗
25. 10.1016/j.biomaterials.2012.04.04710.1016/j.biomaterials.2012.04.047 ↗
26. Volk EL, Rohde K, Rhee M, et al. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res. 2000;60:3514–3521.
27. 10.1016/j.jconrel.2006.07.01110.1016/j.jconrel.2006.07.011 ↗
28. 10.1039/b719950c10.1039/b719950c ↗
29. 10.1016/j.jconrel.2008.11.02510.1016/j.jconrel.2008.11.025 ↗
30. 10.1080/21691401.2017.130721010.1080/21691401.2017.1307210 ↗
31. 10.3109/21691401.2015.105880810.3109/21691401.2015.1058808 ↗
32. 10.1038/sj.bjp.070767810.1038/sj.bjp.0707678 ↗
33. 10.1021/bc300585h10.1021/bc300585h ↗
34. 10.1016/S1525-0016(03)00122-910.1016/S1525-0016(03)00122-9 ↗
35. 10.1155/2011/41472910.1155/2011/414729 ↗
36. 10.1038/mt.2011.31310.1038/mt.2011.313 ↗
37. 10.1016/j.jconrel.2009.05.01910.1016/j.jconrel.2009.05.019 ↗
38. Mohammadi S Mojarrad JS Zakeri-Milani P et al. Synthesis and in vitro evaluation of amphiphilic peptides and their nanostructured conjugates. Adv Pharm Bull. 2015;5:41.
39. 10.1049/iet-nbt.2015.003010.1049/iet-nbt.2015.0030 ↗
40. 10.1002/anie.20110257210.1002/anie.201102572 ↗